Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that a late-breaking abstract from its phase 2 PrTK05 clinical trial evaluating aglatimagene besadenovec (aglatimagene) in localized prostate cancer has been accepted for poster presentation at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.